Elucidation of molecular mechanisms of cancer progression by mechanical unloading
Project/Area Number |
19K22719
|
Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
Allocation Type | Multi-year Fund |
Review Section |
Medium-sized Section 57:Oral science and related fields
|
Research Institution | The University of Tokushima |
Principal Investigator |
HIASA Masahiro 徳島大学, 大学院医歯薬学研究部(歯学域), 講師 (90511337)
|
Project Period (FY) |
2019-06-28 – 2022-03-31
|
Project Status |
Completed (Fiscal Year 2021)
|
Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2019: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 免荷 / 破骨細胞 / メカニカルストレス / がん / 廃用性萎縮 / 骨 |
Outline of Research at the Start |
乳がん、肺がんや多発性骨髄腫は、高頻度で骨転移と骨破壊病変がみられる難治性疾患である。これらのがんの骨破壊病変は骨痛や神経障害、骨折を生じ寝たきりを引き起こすが、寝たきりによる不動は廃用性筋萎縮や骨萎縮、易感染性の原因となり、がんの進展と生存率低下に関与する。故に、寝たきりを如何に防ぐか、寝たきりとなったとしてもがんの進展に直結しないための治療法や機能回復法が望まれる。本研究は、不動(寝たきり)による免荷が骨転移がんの進展・再発を加速化するメカニズムを、免荷による骨髄微小環境の変化と薬剤耐性休眠期がん細胞との関連を中心に解明し、治療法を確立することを目的とする。
|
Outline of Final Research Achievements |
Breast cancer, lung cancer, and multiple myeloma are intractable diseases that frequently develop bone metastasis and osteolytic lesions. Osteolytic lesions of these cancers can cause bone pain, nerve damage, and fractures, which can leave patients bedridden. Furthermore, immobility due to bedridden status causes disuse muscle atrophy, bone atrophy, and increased susceptibility to infection, all of which contribute to cancer progression and poor prognosis. Therefore, it is desired for therapeutic strategies to prevent bedridden patients from directly leading to the progression of cancer. This study elucidated that the mechanism by which immobilization accelerates the progression of bone metastatic cancer involves the activation of osteoclasts, and demonstrated the efficacy of TAK-Pim signaling inhibitors as therapeutic agents targeting for this mechanism.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究は不動(寝たきり)による免荷で生じる骨髄微小環境の変化が、破骨細胞依存的にがん細胞の形質を転換させ、骨転移がんの進展を加速化するメカニズムを解明した。さらに、本研究で開発したTAK-Pimシグナル阻害薬は抗腫瘍作用を有する上に骨形成誘導作用を併せ持ち、転移をも克服することができ難治性のがん治療に光明をもたらす可能性がある。
|
Report
(4 results)
Research Products
(28 results)
-
-
[Journal Article] TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression2022
Author(s)
Tenshin H, Teramachi J, Ashtar M, Hiasa M, Inoue Y, Oda A, Tanimoto K, Shimizu S, Higa Yi, Harada T, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Sebe M, Tsutsumi R, Sakaue H, Endo I, Matsumoto T, Tanaka E, Abe M
-
Journal Title
Clinical & Translational Immunology
Volume: 11
Issue: 1
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Mechanical unloading aggravates bone destruction and tumor expansion in myeloma2022
Author(s)
Tanimoto K, Hiasa M, Tenshin H, Teramachi J, Oda A, Harada T, Higa Y, Sogabe K, Oura M, Sumitani R, Hara T, Endo I, Matsumoto T, Tanaka E, Abe M
-
Journal Title
Haematologica
Volume: 107
Issue: 3
Pages: 744-749
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
[Journal Article] The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.2020
Author(s)
1. Ashtar M, Tenshin H, Teramachi J, Bat-Erdene A, Hiasa M, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Nakamura S, Fujii S, Sumitani R, Miki H, Udaka K, Takahashi M, Kagawa K, Endo I, Tanaka E, Matsumoto T, Abe M.
-
Journal Title
Cancers (Basel)
Volume: 12
Issue: 4
Pages: 929-929
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.2020
Author(s)
2. Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, Nakamura S, Ashtar M, Shimizu S, Iwasa M, Sogabe K, Oura M, Fujii S, Kagawa K, Miki H, Endo I, Haneji T, Matsumoto T, Abe M.
-
Journal Title
Haematologica
Volume: haematol.2019
Issue: 5
Pages: 1401-1413
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Versatile anti-myeloma effects by elotuzumab: impact on gamma delta T cells and osteoclasts2020
Author(s)
T Harada, Y Inoue, H Tenshin, A Oda, M Oura, K Sogabe, R Sumitani, S Fujii, S Nakamura, H Miki, K Kagawa, M Hiasa, J Teramachi, M Abe
Organizer
第82回日本血液学会学術集会
Related Report
-
-
-
[Presentation] 不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる2019
Author(s)
谷本 幸太朗, 日浅 雅博, 天眞 寛文, 寺町 順平, ASHTAR MOHANNAD, 岩佐 昌美, 小田 明日香, 曽我部 公子, 大浦 雅博, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博
Organizer
第37回日本骨代謝学会学術集会
Related Report
-
[Presentation] Mechanical unloading accelerates myeloma tumor expansion.2019
Author(s)
Kotaro Tanimoto, Masahiro Hiasa, Hirohumi Tenshin, Junpei Teramachi, Mohannad Ashtar, Ariunzaya Baterdene, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Kazuhiro Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto, Masahiro Abe
Organizer
29th ANZBMS Annual Scientific Meeting
Related Report
Int'l Joint Research
-
[Presentation] Immobilization promotes bone resorption and tumor expansion in myeloma2019
Author(s)
Kotaro Tanimoto, Masahiro Hiasa, Hirohumi Tenshin, Junpei Teramachi, Mohannad Ashtar, Asuka Oda, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Kazuhiro Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto, Masahiro Abe
Organizer
第81回日本血液学会学術集会
Related Report
-
[Presentation] 不動は骨吸収と骨髄腫進展を促進させる2019
Author(s)
谷本 幸太朗, 日浅 雅博, 天眞 寛文, 寺町 順平, ASHTAR MOHANNAD, 岩佐 昌美, 小田 明日香, 曽我部 公子, 大浦 雅博, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博
Organizer
第44回日本骨髄腫学会学術集会
Related Report
-